Current Location: School> Home > Lecturer

Li yingbo


Research Areas:
Chemical Biology


Education & Positions:

Assistant Professor, Peking University 2011-now
Visiting Scholar, Harvard Medical University, 2016-2017


Research Interests:

Our research interests focus on the biotherapeutic drug development by using a creative combination of chemical biology, molecular biology and cell biology
approaches. The ongoing program including (1) Study of the dynamic interactions between virus and host cells, and development of new biotherapeutic
anti-virus drugs by integrating the approaches of bioorthogonal chemistry, genetic code expansion and glycoprotein modification.(2) target- and phenotypic-
based anti-cancer drug development. (3) Exploring the molecular mechanisms that regulate cancer cell death with small molecules as a tool, and identification of new targets for anti-cancer drugs.


Grants and fundings:

NSF grant (No.81301881) Combination effects of c-Met targeting with irradiation and chemical agents against malignant colon cells harboring a KRAS mutation (2014-2016) Principal Investigator
Programs Foundation of Ministry of Education of China (No. 20130001120034) Anticancer mechanistic study of multi-target agent EMB-3 (2014-2016) Principal Investigator
Peking University Interdisciplinary program (No. BMU2017MX005) Development of cancer diagnostic agent based on the technology of genetic code expansion (2018-2019) Principal Investigator


Selected Publications:

1.Lin S#, Li Y#, Zheng Y, Luo L, Sun Q, Ge Z, Cheng T, Li R. Design, synthesis and biological evaluation of quinazoline-phosphoramidate mustard conjugates as anticancer drugs. Eur J Med Chem. 2017,127:442-458.
2.Li YB, Yan X, Li RD, Liu P, Sun SQ, Wang X, Cui JR, Zhou DM, Ge ZM, Li RT. Discovery of novel heteroarylmethylcarbamodithioates as potent anticancer agents: Synthesis, structure-activity relationship analysis and biological
evaluation. Eur J Med Chem. 2016, 112:217-230.
3.Li Y, Wang J, Gao X, Han W, Zheng Y, Xu H, Zhang C, He Q, Zhang L, Zhou D. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PlosOne.
4.Li YB, Wang ZQ, Yan X, Chen MW, Bao JL, Wu GS, Ge ZM, Zhou DM, Wang YT, Li RT. IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities. Cancer Lett. 2013, 28: 340(1): 88-96.
5.Ouchida AT, Li Y, Geng J, Najafov A, Ofengeim D, Sun X, Yu Q, Yuan J. Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death. Cell Death Dis. 2018, 9(2):138.